{KXLG -South Dakota} Huiza’s subsidiary, King Pharmaceuticals LLC, has started a voluntary recall of a specific secret LA (Penicillin G Benzathine Injectable Suspension) due to the presence of the particle confirmed during the visual test. The recall notice on July 10, 2025, said that the affected product was distributed between December 11, 2023 and June 24, 2025.
The South Dakota Health Department also issued a statement on this recall. The side effects related to this problem have not been reported to date, but Pfizer’s health risk assessment shows “medium” potential risk to patients who are affected by the use of products affected.
The South Dakota Health Department advises that the dosage of Visilin La included in the recall should not be used.
The recall affects a variety of secret LA in 1,200,000 units/2 ml and 2,400,000 units/4 mL configuration. Customers who have been delivered from the affected product are instructed to create a business answer form and return within 5 days of business date. Rapid returning the product to SEDGWICK using the enclosed pre -payment UPS label is requested within 6 months from the notification date. Repayment of returned products is issued through a credit memorandum.
If you ask a question about getting a product return or shipping label, you can contact SEDGWICK (1-800-805-3093). In the case of medical questions about the product, you can contact 800-438-1985 and Options 3 for Pfizer Medical Information. To report side effects or product complaints, the Pfizer Drug Safety is 800-438-1985, and option 1 is provided 7 days a day.
This recall is being carried out with knowledge of the US Food Pharmacy. For more information, including the entire list of affected lots and guidelines, you can find it in the Bicillin recall letter.
